CTLA4 and neoplasm: Anti-CTLA-4 mAb, an approved ICI, activates effector T cells by blocking the inhibitory signaling axis and depleting Tregs at the tumor site through antibody-dependent cellular phagocytosis or antibody-dependent cellular cytotoxicity.